Abbott Laboratories Share Price
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.46 USD | +1.77% |
|
+0.30% | +10.92% |
| 12-12 | Abbott Laboratories Appoints Nita Ahuja to Board of Directors | CI |
| 12-12 | Abbott Laboratories Declares 408th Consecutive Quarterly Cash Common Dividend, Payable on February 13, 2026 | CI |
| Capitalization | 218B 186B 174B 163B 301B 19,760B 329B 2,026B 786B 9,314B 819B 801B 33,982B | P/E ratio 2025 * |
31.5x | P/E ratio 2026 * | 27.3x |
|---|---|---|---|---|---|
| Enterprise value | 222B 189B 177B 166B 306B 20,110B 334B 2,062B 800B 9,480B 833B 816B 34,585B | EV / Sales 2025 * |
4.97x | EV / Sales 2026 * | 4.54x |
| Free-Float |
86.65% | Yield 2025 * |
1.89% | Yield 2026 * | 2.01% |
Last Transcript: Abbott Laboratories
| 1 day | +1.77% | ||
| 1 week | +0.30% | ||
| Current month | -2.67% | ||
| 1 month | -2.61% | ||
| 3 months | -6.18% | ||
| 6 months | -8.05% | ||
| Current year | +10.92% |
| 1 week | 120.7 |  | 125.58 |
| 1 month | 120.7 | | 132.02 |
| Current year | 110.86 | | 141.23 |
| 1 year | 110.86 | | 141.23 |
| 3 years | 89.67 | | 141.23 |
| 5 years | 89.67 | | 142.6 |
| 10 years | 36 | | 142.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 51 | 30/03/2020 |
Philip Boudreau
DFI | Director of Finance/CFO | 52 | 31/08/2023 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 29/02/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Alpern
BRD | Director/Board Member | 74 | 09/10/2008 |
Sally Blount
BRD | Director/Board Member | 63 | 08/12/2011 |
Nancy McKinstry
BRD | Director/Board Member | 66 | 08/12/2011 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 7.18% | 26 M€ | +12.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.77% | +0.30% | +10.19% | +14.59% | 218B | |
| +0.12% | -1.47% | +20.72% | +25.29% | 128B | |
| +0.44% | +1.87% | +49.06% | +106.94% | 67.12B | |
| +0.23% | +3.57% | -11.57% | -20.93% | 57.34B | |
| +1.79% | -0.02% | +16.59% | +73.21% | 51.91B | |
| -2.87% | +2.24% | -15.17% | -42.66% | 26.12B | |
| -0.28% | -4.36% | +16.35% | +29.27% | 24.71B | |
| -1.06% | -3.80% | +5.39% | -35.53% | 23.44B | |
| +0.63% | -2.38% | -25.57% | +15.71% | 21.9B | |
| +0.52% | -2.89% | +8.82% | -1.71% | 20.8B | |
| Average | +0.13% | -0.69% | +7.48% | +16.42% | 63.95B | |
| Weighted average by Cap. | +0.71% | -0.07% | +12.70% | +23.90% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 44.67B 38.06B 35.55B 33.45B 61.58B 4,046B 67.27B 415B 161B 1,907B 168B 164B 6,958B | 48.22B 41.08B 38.37B 36.1B 66.47B 4,367B 72.61B 448B 174B 2,059B 181B 177B 7,511B |
| Net income | 6.93B 5.9B 5.51B 5.19B 9.55B 628B 10.43B 64.35B 24.96B 296B 26B 25.45B 1,079B | 8B 6.81B 6.36B 5.99B 11.02B 724B 12.04B 74.29B 28.82B 341B 30.01B 29.38B 1,246B |
| Net Debt | 3.87B 3.3B 3.08B 2.9B 5.34B 351B 5.83B 35.97B 13.95B 165B 14.53B 14.22B 603B | 861M 733M 685M 644M 1.19B 77.94B 1.3B 7.99B 3.1B 36.74B 3.23B 3.16B 134B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 125.46 $ | +1.77% | 4,765,258 |
| 11/12/25 | 123.28 $ | +0.60% | 5,390,007 |
| 10/12/25 | 122.55 $ | +1.07% | 6,716,496 |
| 09/12/25 | 121.25 $ | -0.69% | 5,229,193 |
| 08/12/25 | 122.09 $ | -2.39% | 6,392,092 |
Delayed Quote Nyse, December 12, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition